Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with SOX and LDRT for Neoadjuvant Treatment of Gastric Cancer
NCT06266871Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of tislelizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by West China Hospital of Sichuan University. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06266871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06266871.